Figure 1. Increased Rab3D in malignant tumor cells and in clinical cancer specimens.

(A). Western Blot analysis of intracellular Rab3D expression in HMEC, non-invasive breast cancer MCF-7, and invasive SKBr-3, MDA-MB-231 cell lines. (B). Western Blot analysis of intracellular Rab3D expression in melanoma F0, F1, F10 cell lines. (C) Western Blot analysis of intracellular Rab3D expression in lung cancer A549, H-1299 cell lines and ovary cancer Hela cell line. (D). Representative Rab3D staining in normal tissues, benign tumor and malignant breast cancer samples that illustrate immunohistochemical scores of 0, 1, 2 and 3. Scale bar, 100 μm. (E). Association of Rab3D immunohistochemical scores with tumor malignancy. The x² test was used to test difference between categorical variables. (F). Representative Rab3D staining in different stages of malignant breast cancer samples that illustrate immunohistochemical scores of 0, 1, 2 and 3. Scale bar, 100 μm. (G). Associations of Rab3D immunohistochemical scores with tumor stage (I, II, III-IV) and tumor grade (1, 2, and 3). The x² test was used to test difference between categorical variables.